These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30780892)

  • 1. Preservation of ovarian function and fertility despite gonadotoxic chemotherapy.
    Blumenfeld Z
    Expert Rev Endocrinol Metab; 2012 Sep; 7(5):567-576. PubMed ID: 30780892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
    Blumenfeld Z
    Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
    Blumenfeld Z; Evron A
    Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of gonadotropin-releasing hormone agonists in female fertility preservation.
    Lee JH; Choi YS
    Clin Exp Reprod Med; 2021 Mar; 48(1):11-26. PubMed ID: 33648041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women.
    Blumenfeld Z; Avivi I; Ritter M; Rowe JM
    J Soc Gynecol Investig; 1999; 6(5):229-39. PubMed ID: 10554760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
    Blumenfeld Z
    Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH-agonists in fertility preservation.
    Blumenfeld Z
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):523-8. PubMed ID: 18971681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and fertility.
    Blumenfeld Z
    Best Pract Res Clin Obstet Gynaecol; 2012 Jun; 26(3):379-90. PubMed ID: 22281514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
    Garrido-Oyarzún MF; Castelo-Branco C
    Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
    Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
    Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy.
    Blumenfeld Z
    Clin Med Insights Reprod Health; 2019; 13():1179558119870163. PubMed ID: 31488958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-Releasing Hormone (GnRH) Agonists Do Not Protect Ovarian Function in Patients Undergoing Stem Cell Transplants.
    Benor A; Decherney A
    Cureus; 2024 Apr; 16(4):e58387. PubMed ID: 38756303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
    Danis RB; Pereira N; Elias RT
    Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer and Fertility Preservation in Young Female Patients: A Systematic Review of the Literature.
    Boutas I; Kontogeorgi A; Koufopoulos N; Dimas DT; Sitara K; Kalantaridou SN; Dimitrakakis C
    Clin Pract; 2023 Nov; 13(6):1413-1426. PubMed ID: 37987428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian protection and fertility preservation in women with cancer: A French national registry analysis between 2005 and 2014.
    Phelippeau J; Cazalis CG; Koskas M
    J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):705-710. PubMed ID: 31276847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy.
    Blumenfeld Z
    Curr Opin Obstet Gynecol; 2003 Oct; 15(5):359-70. PubMed ID: 14501238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryopreservation of ovarian tissue for fertility preservation in young female oncological patients.
    Andersen CY; Kristensen SG; Greve T; Schmidt KT
    Future Oncol; 2012 May; 8(5):595-608. PubMed ID: 22646773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
    Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.